Related Experiment Video
Updated: Jan 24, 2026

Generating Transposon Insertion Libraries in Gram-Negative Bacteria for High-Throughput Sequencing
Published on: July 7, 2020
Second-Generation Tryptamine Derivatives Potently Sensitize Colistin Resistant Bacteria to Colistin
Bradley M Minrovic1, Veronica B Hubble1, William T Barker1
1Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556, United States.
Abstract:
Antibiotic resistance has significantly increased since the beginning of the 21st century. Currently, the polymyxin colistin is typically viewed as the antibiotic of last resort for the treatment of multidrug resistant Gram-negative bacterial infections. However, increased colistin usage has resulted in colistin-resistant bacterial isolates becoming more common. The recent dissemination of plasmid-borne colistin resistance genes (mcr 1-8) into the human pathogen pool is further threatening to render colistin therapy ineffective. New methods to combat antibiotic resistant pathogens are needed. Herein, the utilization of a colistin-adjuvant combination that is effective against colistin-resistant bacteria is described. At 5 μM, the lead adjuvant, which is nontoxic to the bacteria alone, increases colistin efficacy 32-fold against bacteria containing the mcr-1 gene and effects a 1024-fold increase in colistin efficacy against bacteria harboring chromosomally encoded colistin resistance determinants; these combinations lower the colistin minimum inhibitory concentration (MIC) to or below clinical breakpoint levels (≤2 μg/mL).
Insights
A novel colistin-adjuvant combination effectively combats antibiotic-resistant Gram-negative bacteria. This adjuvant significantly boosts colistin efficacy against resistant strains, restoring treatment options.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Antibiotic resistance, particularly to polymyxin colistin, is a growing global health threat.
- Emergence of plasmid-borne colistin resistance genes (mcr 1-8) compromises last-resort antibiotic efficacy.
- Multidrug-resistant Gram-negative bacterial infections necessitate novel therapeutic strategies.
Purpose of the Study:
- To investigate a colistin-adjuvant combination therapy for combating colistin-resistant bacteria.
- To evaluate the efficacy of a lead adjuvant in restoring colistin's effectiveness.
Main Methods:
- Testing a lead adjuvant at 5 μM in combination with colistin.
- Assessing adjuvant efficacy against bacteria with plasmid-borne (mcr-1) and chromosomal colistin resistance.
- Determining the fold-increase in colistin efficacy and minimum inhibitory concentration (MIC) reduction.
Main Results:
- The lead adjuvant, non-toxic alone, significantly enhanced colistin efficacy.
- A 32-fold increase in colistin efficacy was observed against mcr-1 harboring bacteria.
- A 1024-fold increase in colistin efficacy was achieved against chromosomally resistant bacteria.
- Combinations reduced colistin MIC to clinically relevant levels (≤2 μg/mL).
Conclusions:
- Colistin-adjuvant combination therapy presents a promising strategy against colistin-resistant Gram-negative pathogens.
- This approach can restore the clinical utility of colistin for treating challenging infections.
- Further research into adjuvant-based therapies is warranted to address the antibiotic resistance crisis.
More Related Videos
Related Concept Videos
Resistivity
Resistance
The Roles of Bacteria and Fungi in Plant Nutrition
Resistance and Conductance
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...
Equivalent Resistance
The Tree of Life - Bacteria, Archaea, Eukaryotes

